整合素αVβ3与胃泌素释放肽受体(GRPR)双靶点放射性示踪剂[68Ga]Ga-RGD-RM26-03的合成、临床前及初步临床评价
本研究设计合成整合素αVβ3与GRPR双靶点异二聚体LNC1015,在PC3荷瘤模型中行microPET与生物分布检测,并在乳腺癌患者中开展[68Ga]Ga-LNC1015 PET/CT初步临床可行性研究,与[18F]FDG PET/CT比较。结果显示[68Ga]Ga-LNC1015在盐水中至少2小时稳定,肿瘤摄取与滞留优于单体[68Ga]Ga-RGD和[68Ga]Ga-RM26,临床中病灶摄取与靶本比显著高于[18F]FDG PET/CT。
要点
- [68Ga]Ga-LNC1015在盐水中至少稳定2小时,体外与体内显示良好结合亲和力与特异性。
- 在所有检测时间点,[68Ga]Ga-LNC1015的肿瘤摄取与滞留均优于单体[68Ga]Ga-RGD和[68Ga]Ga-RM26。
- 乳腺癌患者中,[68Ga]Ga-LNC1015 PET/CT原发灶与转移灶的肿瘤摄取及靶本比显著高于[18F]FDG PET/CT。
核心结论
- 双靶点放射性示踪剂[68Ga]Ga-LNC1015的肿瘤摄取与滞留显著改善,肝脏摄取低于[68Ga]Ga-RGD和[68Ga]Ga-RM26单体。
- 首次人体研究显示患者中靶本比高,提示良好的药代动力学与较高的肿瘤PET/CT成像临床可行性。
研究设计与样本
- 设计并合成连接环状RGD与RM26肽的异二聚体LNC1015([68Ga]Ga-RGD-RM26-03)。
- 在PC3荷瘤模型中使用microPET与生物分布研究进行临床前药代动力学检测。
- 在乳腺癌患者中开展[68Ga]Ga-LNC1015 PET/CT的临床可行性研究,并与[18F]FDG PET/CT结果比较。
主要发现
- [68Ga]Ga-LNC1015在盐水中至少2小时稳定性良好,体外和体内显示良好的结合亲和力与特异性。
- 在所有检测时间点,[68Ga]Ga-LNC1015在PET成像中的肿瘤摄取与滞留均优于其单体[68Ga]Ga-RGD和[68Ga]Ga-RM26。
- 在初步临床研究中,[68Ga]Ga-LNC1015 PET/CT原发灶与转移灶的肿瘤摄取及靶本比(TBR)显著高于[18F]FDG PET/CT,获得高病灶检出率与肿瘤勾画。
临床怎么用
- 作者认为[68Ga]Ga-LNC1015首次人体研究显示患者中高靶本比,提示良好的药代动力学与较高的肿瘤PET/CT成像临床可行性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Integrin receptor αvβ3 and gastrin-releasing peptide receptor (GRPR) expression of tumors could be detected using PET imaging with radiolabeled Arg-Gly-Asp (RGD) and the antagonistic bombesin analog RM26, respectively. The purpose of this study was to investigate the dual receptor-targeting property of the heterodimer RGD-RM26-03 (denoted as LNC1015), demonstrate the tumor diagnostic value of [68Ga]Ga-LNC1015 in preclinical experiments, and evaluate its preliminary clinical feasibility. METHODS: LNC1015 was designed and synthesized by linking cyclic RGD and the RM26 peptide. Preclinical pharmacokinetics were detected in a PC3 xenograft model using microPET and biodistribution studies. The clinical feasibility of [68Ga]Ga-LNC1015 PET/CT was performed in patients with breast cancer, and the results were compared with those of 18F-fluorodeoxyglucose (FDG). RESULTS: [68Ga]Ga-LNC1015 had good stability in saline for at least 2 h, and favorable binding affinity and specificity were demonstrated in vitro and in vivo. The tumor uptake and retention of [68Ga]Ga-LNC1015 during PET imaging were improved compared with its monomeric counterparts [68Ga]Ga-RGD and [68Ga]Ga-RM26 at all the time points examined. In our initial clinical studies, the tumor uptake and tumor-to-background ratio (TBR) of primary and metastatic lesions in [68Ga]Ga-LNC1015 PET/CT were significantly higher than those in [18F]FDG PET/CT, resulting in high lesion detection rate and tumor delineation. CONCLUSION: The dual targeting radiotracer [68Ga]Ga-LNC1015 showed significantly improved tumor uptake and retention, as well as lower liver uptake than [68Ga]Ga-RGD and [68Ga]Ga-RM26 monomer. The first-in-human study showed high TBRs in patients, suggesting favorable pharmacokinetics and high clinical feasibility for PET/CT imaging of cancer.
引用
- Wen X, Wang R, Xu P, et al. Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376806. doi:10.1007/s00259-024-06634-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。